Graft

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to register today!

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Neuberger, J.
Right arrow Search for Related Content
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Graft, Vol. 6, No. 2, 110-119 (2003)
DOI: 10.1177/1522162803256718
© 2003 SAGE Publications

Immunosuppression after Liver Transplantation

James Neuberger, DM, FRCP

Liver Unit Queen Elizabeth Hospital, J.M.Neuberger{at}bham.ac.uk

The purpose of immunosuppression is to prevent the recipient's immune system from destroying or damaging the graft. Immunosuppression aims to balance under-immunosuppression leading to graft rejection and over-immunosuppression leading to sepsis and malignancy. There have been comparatively few studies on which to base a rational approach to immunosuppression. The types of immunosuppressants are 1) purine analogues such as 6-mercaptopurine (6-MP), 2) inhibitors of inosine monophosphate dehydrogenase such as myciphenolate mofetil (MMF), 3) glucocorticoids such as prednisone, 4) calcineurin binding drugs such as cyclosporin and tacrolimus, 5) TOR inhibitors such as sirolimus, and 6) mono- and polyclonal antibodies. There are five phases in the management of immunosuppression: 1) induction, 2) maintenance, 3) treatment of acute rejection, 4) treatment of chronic rejection, and 5) withdrawal of immunosuppression. Immunosuppression is complicated by intercurrent infection, usually viral or tubucular, and by pregnancy, breast feeding, diabetes mellitus, and renal impairment.

Key Words: liver transplantation • calicineurin inhibitors • anti-CD3

References

  • 1. Micromedex Information System. http://www.micromedex.com; info@mdx.com
  • 2. Devlin J, Doherty D, Thomson L, Wong T, Donaldson P, Portmann B, et al. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 1998;27:926-933.[Medline] [Order article via Infotrieve]OpenURL
  • 3. Jain A, Kashyap R, Marsh W, Rohal S, Khanna A, Fung JJ. Reasons for long-term use of steroid in primary adult liver transplantation under tacrolimus. Transplantation 2001;71(8):1102-1106.[Medline] [Order article via Infotrieve]OpenURL

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Neuberger, J.
Right arrow Search for Related Content
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?